{"id":"W4405049511","doi":"10.1182/blood-2024-200268","title":"A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Tofacitinib; Phases of clinical research; Janus kinase inhibitor; Pharmacology; Investigational Drugs; Internal medicine; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002121469,0.002104991,0.002198709,0.0005056823,0.0005627096,0.001312993,0.0009861069,0.001620456,0.004743736],"category_scores_gemma":[0.001110749,0.0009682217,0.002033236,0.000445026,0.001153262,0.001302148,0.0004012036,0.004632382,0.001272188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001261659,"about_ca_system_score_gemma":0.001962136,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001465096,"about_ca_topic_score_gemma":0.003199576,"domain_scores_codex":[0.9994648,0.0002372912,0.00002509391,0.0001130347,0.00004645647,0.0001132723],"domain_scores_gemma":[0.9992036,0.0001113623,0.0001022386,0.00006799201,0.00005537029,0.0004594431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7040707,0.1734299,0.003803867,0.001008824,0.001739539,0.0004685715,0.0003741539,0.002111581,0.04217498,0.0003240139,0.005011107,0.06548285],"study_design_scores_gemma":[0.5580047,0.4294274,0.005931115,0.00003121286,0.000551606,0.0002840589,0.00005226792,0.0009457975,0.002299381,0.0002263931,0.002211277,0.00003495005],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873051,0.003153369,0.0008054725,0.0008078453,0.0002669534,0.003311586,0.001811862,0.0001257327,0.00241215],"genre_scores_gemma":[0.9826037,0.002810056,0.002515562,0.001467548,0.0003164366,0.003446079,0.003222317,0.00004151473,0.00357683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004743736,"threshold_uncertainty_score":0.01586932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01300474013605575,"score_gpt":0.2724617725301055,"score_spread":0.2594570323940497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}